New Dual-Target Nanoparticles Fix Lung and Liver Damage in One Treatment

Alpha-1 antitrypsin deficiency (AATD) is a hereditary condition caused by a mutation in the SERPINA1 gene. The faulty protein misfolds and accumulates in the liver, causing progressive liver damage, while a shortage of functional A1AT in the lungs leaves them vulnerable to destruction by neutrophil elastase — ultimately leading to emphysema. Treating AATD is complicated because both organs must be addressed simultaneously, something existing gene-editing delivery systems have been unable to accomplish efficiently.

Researchers engineered a new class of lipid nanoparticles called Dual Selective ORgan-Targeting LNPs (Dual SORT LNPs), designed to shuttle base-editing machinery to both the liver and lung tissue after a single administration. Base editing is a precise gene-editing approach that chemically rewrites individual DNA letters without creating double-strand breaks, reducing the risk of unintended mutations.

In preclinical testing, the Dual SORT LNPs corrected the PiZ mutation in approximately 40% of liver cells and 10% of lung alveolar type 2 (AT2) cells. Critically, liver corrections remained stable over 32 weeks of observation, with toxic Z-A1AT protein levels dropping by more than 80% and liver tissue returning to a healthy phenotype. In lung tissue, the treatment achieved 89% inhibition of neutrophil elastase activity in bronchoalveolar lavage fluid, suggesting meaningful functional protection against emphysema.

These results demonstrate that durable, multi-organ genome correction is achievable with a single nanoparticle platform, which could transform treatment strategies for diseases requiring simultaneous editing of multiple tissue types.

Caveats include the fact that results are preclinical and translation to humans remains unproven. Lung editing efficiency at 10% may need improvement to achieve full clinical benefit, and long-term safety data beyond 32 weeks is not yet available.